Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.36 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.34 |
| ▸ | CDC25B | P30305 | 6/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174055 | 1.00 | TACR2 (0.36) | TACR2ERN1PTPN1CDC25BNT5E | |
| SCHEMBL20741919 | 0.92 | ERN1 (0.35) | TACR2ERN1PTPN1CDC25BNT5E | |
| SCHEMBL20139433 | 0.90 | TACR2 (0.37) | TACR2ERN1PTPN1CDC25BNT5E | |
| SCHEMBL2960359 | 0.84 | TACR2 (0.37) | TACR2PTPN1CDC25BNT5EPTPN2 | |
| SCHEMBL2960356 | 0.84 | TACR2 (0.37) | TACR2PTPN1CDC25BNT5EPTPN2 | |
| SCHEMBL2172332 | 0.83 | TACR2 (0.33) | TACR2PTPN1CDC25BNT5EPTPN2 | |
| SCHEMBL2172327 | 0.83 | TACR2 (0.33) | TACR2PTPN1CDC25BNT5EPTPN2 | |
| SCHEMBL20139455 | 0.82 | TACR2 (0.36) | TACR2ERN1PTPN1CDC25BNT5E | |
| SCHEMBL20140011 | 0.81 | NT5E (0.35) | TACR2PTPN1CDC25BNT5EPTPN2 | |
| SCHEMBL589372 | 0.80 | ERN1 (0.36) | TACR2ERN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076503-B1 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A1 | TACR2 957/4885ERN1 1890/4885PTPN1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.